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ABSTRACT
Elevated hepatic glucose production, impaired insulin secretion, and insulin resistance – abnormalities 
of glucose metabolism typically found in subjects with obesity – are major factors underlying the 
pathogenesis of type 2 diabetes (DM2) and the metabolic syndrome (MS). Adiponectin is a major 
regulator of glucose and lipid homeostasis via its insulin-sensitizing properties, and lower levels 
seems to be associated with the development of DM2 and MS. The purpose of this review is to clarify 
the mechanisms whereby adiponectin relates to the development of DM2 and MS and the association 
between polymorphisms of the adiponectin gene, circulating levels of the hormone, and its 
relationships with DM2. In addition, the impact of dietary lipids in the circulating levels of adiponectin 
will be addressed. According to the literature, circulating adiponectin levels seem to decrease as 
the number of MS components increases. Lower adiponectin concentrations are associated with 
higher intra-abdominal fat content. Therefore, adiponectin could link intra-abdominal fat with insulin 
resistance and development of MS. Therapeutic strategies that target the MS and its components, 
such as lifestyle modification through physical activity and weight loss, have been shown to 
increase adiponectin concentrations. Possible roles of diets containing either low or high amounts 
of fat, or different types of fat, have been analyzed in several studies, with heterogeneous results. 
Supplementation with n-3 PUFA modestly increases adiponectin levels, whereas conjugated linoleic 
acid supplementation appears to reduce concentrations when compared with unsaturated fatty acid 
supplementation used as an active placebo. Arch Endocrinol Metab. 2017;61(6):614-22
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INTRODUCTION
T he prevalence of the metabolic syndrome (MS) and diabetes mellitus type 2 (DM2) in the North 
American population is 22.9% and 9.3%, respectively, 
according to NHANES and CDC data (1,2). Very similar 
prevalence figures have been reported in Brazil (3). In a 
recent systematic review of cross-sectional studies, the 
weighted average prevalence of MS was 29.8%, 20.1%, 
and 41.5% in the adult Brazilian population in urban, 
rural, and indigenous areas, respectively (3). According 
to the results of a study conducted with fixed-shift 
industry workers in the state of Rio Grande do Sul, 
being female, being older, and having sleep deprivation 
proved to be potential risk factors for MS, while having 
a higher education and eating a greater number of 
meals per day were considered protective factors 
against MS (4). Regarding DM2, the Multicenter 
Study on the Prevalence of Diabetes in Brazil 
estimated its prevalence the adult population at 7.6% 
in the late 1980s (5). According to 2012 data, 7.4% 
of respondents to a telephone survey representative of 
the entire adult population of all 26 state capitals and 
the Federal District reported a medical diagnosis of 
DM2 (6). Complications from DM2 result in high 
morbidity and mortality and an average 6-year reduction 
in average life expectancy when the disease is diagnosed 
at age 50 (7). The direct and indirect costs of DM2 
amount to US$ 245 billion a year in the United States 
alone. Health expenditures on individuals with DM2 
are increased twofold when compared to spending on 
individuals without the disease (1). In Brazil, DM is also 
considered a major public health problem. Its estimated 
cost per capita is US$ 1527.6/year; considering that an 
estimated 11.6 million Brazilians aged 20 to 79 have 
DM2, direct expenses related to this condition amount 
to approximately US$ 17 billion a year (8). 
Obesity is associated with development of the MS, 
which is characterized by a cluster of risk factors for 
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cardiovascular disease and DM2, such as hyperglycemia, 
elevated blood pressure, elevated triglycerides, low 
HDL cholesterol, and central obesity (9). Moreover, 
obesity and abdominal fat deposition cause a number of 
metabolic abnormalities that result in increased hepatic 
glucose output and decreased insulin sensitivity in 
skeletal muscle, liver, and adipose tissue – processes that 
are closely related to the pathogenesis of DM2 (10). 
In view of the foregoing, the present review sought 
to clarify the mechanisms whereby the hormone 
adiponectin relates to the development of MS and 
DM2. The association between polymorphisms of the 
adiponectin gene, circulating levels of the hormone 
it encodes, and its relationships with DM2 will also 
be explored. In addition, the impact of diets with 
different levels and types of lipids on circulating levels 
of adiponectin will be addressed.
ADIPONECTIN AND GLUCOSE METABOLISM
Adiponectin, a hormone present mainly in adipose 
tissue, is encoded by the APM1 gene (chromosome 
3q27). In humans, adiponectin plasma levels range from 
3 to 30 µg/mL, which is among the highest plasma 
concentrations of a circulating protein. The adiponectin 
molecule is a 247-amino acid polypeptide and is secreted 
into circulation in three oligomeric isoforms: a low-
molecular-weight trimer, an intermediate-molecular-
weight hexamer and a high-molecular-weight complex 
(11). Some studies suggest that the high-molecular-
weight isoform is most biologically active, and that 
lower levels of this form are associated with DM and 
coronary artery disease (12-14). Adiponectin acts 
through two receptors, AdipoR1 and AdipoR2; the 
former is expressed at higher levels in muscle tissue, and 
the latter, in liver tissue. Studies have demonstrated that 
the AdipoR1 receptor is also present in endothelial cells 
(15), cardiomyocytes (16), and pancreatic beta cells 
(17), while AdipoR2 is present in endothelial cells (18), 
and both receptors are present in the hypothalamus 
(19). Resistance to the action of insulin resulting 
from obesity causes downregulation of adiponectin 
receptors in muscle and liver (20). Furthermore, 
adiponectin expression blunts increases in insulin, 
TNF-α, endothelin-1, and glucocorticoids, factors 
implicated in the pathogenesis of insulin resistance, 
subclinical inflammation, endothelial dysfunction, and 
regulation of energy metabolism, and closely related 
to the development of MS, DM2, and cardiovascular 
disease (21). Accordingly, extensive research has shown 
that adiponectin levels are reduced in obesity (22,23), 
DM2 (22,24), and coronary artery disease (25-27).
To test the in vivo effect of adiponectin on insulin 
sensitivity, a lipoatrophy mouse model with adiponectin 
deficiency was developed. In these animals, replacement 
of physiological doses of adiponectin improved insulin 
resistance (28). Adiponectin stimulated fatty acid 
oxidation in muscle by increasing the expression of 
molecules involved in the transport of fatty acids 
(CD36), their combustion (acetyl coenzyme A 
oxidase), and dissipation of energy through increased 
expression of type 2 uncoupling protein (UCP-2) (28). 
Adiponectin replacement in these animals increased 
PPAR-alpha expression, fatty acid oxidation, and 
energy consumption, causing a reduction of triglyceride 
levels in muscle and liver tissue (28). The reduction in 
triglyceride content in skeletal muscle was associated 
with increased translocation of GLUT-4, which led 
to improved insulin sensitivity (28). In another study 
by the same group, acute treatment (up to 6 hours) 
of C2C12 myoblasts with adiponectin increased the 
oxidation of fatty acids and stimulated glucose uptake 
via activation of AMPK (29), leading to a reduction in 
levels of enzymes that indicate hepatic gluconeogenesis. 
Furthermore, wild-type mice that received a diet rich 
in total lipids had a reduction in adiponectin levels 
compared to a diet rich in carbohydrates. Adiponectin 
replacement in these animals also improved insulin 
resistance and hypertriglyceridemia induced specifically 
by the high-fat diet (28). Additionally, studies 
demonstrated in wild-type and ob/ob or streptozotocin-
induced DM1 mouse models that an acute increase 
in circulating levels of adiponectin leads to a transient 
decrease in baseline glucose level by inhibiting enzymes 
involved in hepatic gluconeogenesis and hepatic glucose 
production rate (30,31). Based on these studies, it was 
demonstrated that stimulation of fatty acid oxidation in 
muscle and liver, increasing glucose uptake in skeletal 
muscle and suppressing hepatic gluconeogenesis, are 
potential routes through which adiponectin regulates 
insulin sensitivity (28,30,31). These data suggest that 
insulin resistance associated with a high-fat diet and 
obesity are partly related to a reduction in circulating 
adiponectin levels and that an increase of these levels 
would protect against the development of different 
components of MS, especially those related to the 
modulation of insulin sensitivity, body fat distribution, 
and lipoprotein metabolism (28).
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Studies have suggested a relationship between 
adipokines, such as letptin and resistin, and DM-related 
vascular complications (32,33). Chronic kidney disease 
is considered a long-term complication of DM, and its 
development has been associated with higher levels of 
these adipokines (34). According to an experimental 
study, adipokines can lead to kidney injury by 
regulation of endothelial dysfunction, oxidative stress, 
and inflammatory processes (35). A longitudinal study 
of 161 subjects with diabetes followed from 2002 to 
2013 demonstrated that plasma adiponectin increased 
in patients with renal insufficiency, and that its levels 
were positively associated with albuminuria (36). It is 
interesting to highlight that, in the context of chronic 
kidney disease, higher levels of adiponectin have been 
found to predict progression to end-stage renal disease 
(ESRD), cardiovascular mortality, and total mortality 
(37,38). Adiponectin levels are known to increase with 
decreasing glomerular filtration rate in chronic kidney 
disease, as a reflection of decreased renal clearance (39). 
As a result, ESRD features increased adiponectin levels 
and AdipoR1 expression (40). Both mechanisms may 
explain the association between higher adiponectin 
levels and total and cardiovascular mortality in this 
scenario.  
ASSOCIATION BETWEEN ADIPONECTIN GENE 
POLYMORPHISMS, CIRCULATING ADIPONECTIN 
LEVELS, AND DM2
Epidemiological studies have shown that DM2 clusters 
in families, suggesting a genetic contribution to its 
development. The cumulative risk of DM2 at age 65 
was 14.8% for individuals with no family history of 
DM2, 22% for individuals with only one parent with 
DM2, and 41% for individuals whose parents are both 
affected by the disease (41). 
Recent studies have shown that a number of genetic 
polymorphisms are associated with the development 
of obesity and DM2 (42,43). Genes that modulate 
the metabolism of adipose tissue and, consequently, 
are involved in the fatty acid synthesis and metabolism 
pathways are important determinants of body fat 
distribution and insulin sensitivity, which, in turn, are 
also related to abnormalities in glucose metabolism 
and development of DM2. Genetic variants of the 
adiponectin gene have also been associated with 
resistance to insulin action and DM2 (44).
It is estimated that 39-46% of the variability of 
circulating adiponectin levels is due to genetic factors 
(45,46). In this regard, a recent systematic review and 
meta-analysis compiled data from seven studies that 
explored the association between three single-nucleotide 
polymorphisms (SNPs), -11391G→A, +45T→G, and 
+276G→T, and plasma level of adiponectin (25). The 
-11391G→A SNP was associated with higher levels of 
circulating adiponectin in subjects carrying the A allele 
compared to subjects carrying only the G allele. No 
association was found between the +45T→G SNP and 
adiponectin levels. Regarding the SNP +276G→T, 
adiponectin levels showed a progressive increase in 
homozygotes for the G allele when compared to 
heterozygotes and homozygotes for the T allele (25).
Associations between adiponectin gene 
polymorphisms and risk of DM2 have also been 
widely explored in the literature. Among the nine 
chromosomal regions related to DM2, three (3q, 15q, 
and 20q) are found in various ethnic groups, such as 
the Japanese, German, and French (47). Interestingly, 
the 3q27 region containing the adiponectin gene once 
again suggests a role of adiponectin as a determinant 
of susceptibility to DM2. The 276 SNP in intron 2 (G 
vs. T) has been associated with distinct phenotypes of 
adiponectin levels, insulin resistance, and susceptibility 
to DM2. Individuals with the G/G genotype at 
position 267 had lower adiponectin levels and increased 
DM2 risk compared with T/T genotype carriers (24). 
Similar associations between the adiponectin gene and 
susceptibility to DM2 have also been demonstrated in 
German and French populations (48,49).
Given the large number of studies that have sought 
associations between different polymorphisms of 
the adiponectin gene and DM2, a recent systematic 
review and meta-analysis pooled the results of more 
than 2,000 individuals with DM2 vs. controls for four 
SNPs: -11391G→A, -11377C→G, +45T→G, and 
+276G>T (25). No association was demonstrated 
between the evaluated SNPs and risk of DM2. 
Subsequently, another systematic review and meta-
analysis of 45 studies (9,986 individuals with DM2 vs. 
16,222 control subjects) only assessed polymorphism 
+45T→G and, through a subgroup analysis, found 
an association between +45T→G and risk of DM2 
in studies involving Asians. However, there was no 
such association in studies involving Caucasians (50). 
Regarding insulin resistance, an association between 
the +276G→T SNP and insulin resistance estimated 
Co
py
rig
ht
©
 A
E&
M
 a
ll r
ig
ht
s r
es
er
ve
d.
617
Adiponectin and metabolic diseases
Arch Endocrinol Metab. 2017;61/6
by HOMA-IR has been observed. Resistance to 
insulin action was higher in individuals homozygous 
for the G allele compared to heterozygotes and those 
homozygous for the T allele, indicating higher insulin 
sensitivity in individuals carrying the T allele – the 
same allele that showed a trend toward association with 
higher levels of adiponectin (25).
In summary, studies  have suggested that genetic 
factors modulate circulating adiponectin levels (27). 
Additionally, adiponectin gene variants have been 
associated with higher risk of developing DM2 and MS, 
especially in phenotypes associated with insulin resistance 
(51). However, this finding remains controversial.
ADIPONECTIN AND THE METABOLIC SYNDROME
Studies have suggested that expression of the APM1 gene 
in visceral abdominal fat is lower than in subcutaneous 
abdominal fat (52,53). This gene expression in adipose 
tissue correlates significantly with plasma levels, being 
higher in lean individuals and those with higher 
sensitivity to insulin action (23). Furthermore, the 
lowest concentration of adiponectin is associated more 
strongly with quantification of visceral abdominal fat 
than with subcutaneous abdominal fat, suggesting a 
possible relationship with MS (54).
The inverse relation between adiponectin levels 
and criteria for MS has been described in the literature 
(47,55-58). It is well demonstrated that overweight 
individuals have lower levels of adiponectin compared to 
lean individuals, and that levels of this hormone decrease 
as BMI increases in men and women (55). In addition, 
higher levels of adiponectin were associated with a lower 
incidence of DM2 in a Japanese cohort followed for 5 
years in order to better understand the factors related 
to development of DM. Individuals in the lowest tertile 
of adiponectin levels developed approximately nine 
times more DM2 than those individuals belonging 
to the highest tertile (56). Additionally, individuals 
with lower plasma levels of adiponectin have LDL-
cholesterol molecules of smaller size, lower lipoprotein 
lipase activity, lower HDL-cholesterol levels, and higher 
triglyceride levels (47,58). Regarding blood pressure, 
lower levels of circulating adiponectin were observed 
in hypertensive compared to non-hypertensive patients, 
even after adjusting for obesity, insulin resistance, 
and DM2 (57). Studies have suggested an effect 
of adiponectin on blood pressure homeostasis. An 
increase in collagen deposition promoted by increased 
serum levels of procollagen type I carboxy-terminal 
propeptide (PICP) is associated with an acceleration 
of the arterial stiffening process, a phenomenon closely 
related to the development of hypertension (59) and 
MS (60). A cross-sectional study of 188 hypertensive 
patients without DM2 showed that higher adiponectin 
levels were associated with lower circulating levels of 
PICP (61). Reinforcing this hypothesis, lower levels of 
adiponectin were associated with increased arterial wall 
stiffness in a cohort of elderly individuals (62). An effect 
of adiponectin on endothelial function has also been 
demonstrated. Adiponectin increases gene expression 
and activates endothelial nitric oxide synthase through 
activation of AMPK (63), stimulating the synthesis 
of nitric oxide, an important endothelial factor and 
potent vasodilator (64). Additionally, it is known that 
the renin-angiotensin system plays an important role in 
regulating blood pressure and that, when activated, it 
perpetuates the inflammatory process in the arterial wall, 
increasing oxidative stress and fostering development 
of atherosclerosis (65,66). Through its antioxidant 
and anti-inflammatory effects, adiponectin inhibits the 
deleterious vascular effect of renin-angiotensin system 
activation and is closely related to dysregulation of 
blood pressure homeostasis in MS (67). Figure 1 shows 
the different mechanisms involved in the pathogenesis 
of MS related to hypoadiponectinemia.
Cross-sectional studies have evaluated the 
associations between the different MS components 
and adiponectin levels in populations with different 
metabolic profiles (68-70). The results of a cross-
sectional study conducted in the elderly U.S. Rancho 
Bernardo cohort demonstrated that individuals with MS 
had lower circulating levels of adiponectin compared 
to individuals without MS (68). Furthermore, 
the presence of each of the MS components was 
associated with lower levels of adiponectin (68). Koh 
and cols. included only Asian individuals over the 
age of 40, and found that lower adiponectin levels 
were associated with greater waist circumference and 
increased levels of triglycerides, CRP, fasting glucose, 
and insulin. Furthermore, individuals with higher 
circulating adiponectin had higher HDL-cholesterol 
levels (69). In a study conducted by von Frankenberg 
and cols. in Brazil, individuals were referred to a 
tertiary care hospital (Hospital de Clínicas de Porto 
Alegre, state of Rio Grande do Sul) for screening and 
evaluation of glucose metabolism abnormalities and 
MS. A replication analysis was performed in subjects 
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Figure 1. Mechanisms whereby a reduction in adiponectin levels is associated with the development of MS. 1: Accumulation of visceral fat reduces 
production of adiponectin. Tissue inflammation increases levels of C-reactive protein (CRP) and inflammatory cytokines (TNF-α and interleukin-6), 
activating hepatic gluconeogenesis. 2: Hepatic gluconeogenesis is activated and insulin sensitivity in muscle and liver is further reduced, resulting in 
increased circulating glucose levels. 3 and 4: Reduction of triglyceride oxidation from adipose tissue and dietary lipids by the liver increases levels of free 
fatty acids (FFA) and production of VLDL, generating an imbalance in lipid profile (increased LDL cholesterol, triglycerides [TG], and reduced HDL 
cholesterol). 5: Increased serum level of procollagen type I carboxy-terminal propeptide (PICP) intensifies arterial stiffness, and reduced nitric oxide 
production contributes to reduced vasodilation. These mechanisms, along with the pro-inflammatory environment, promote changes in blood pressure 
homeostasis, which contribute to the development of systemic arterial hypertension.
undergoing cardiac catheterization at another tertiary 
referral center (Hospital São Paulo, in the city of São 
Paulo). This study demonstrated that levels of total and 
high-molecular-weight adiponectin were lower in the 
presence of MS, and were reduced with each increase in 
the number of components of MS. Adiponectin levels 
were mainly determined by their relation with HDL 
cholesterol, triglycerides, and waist circumference. In 
addition, blood glucose, subclinical inflammation, and 
insulin resistance partially explained why adiponectin 
levels were lower in individuals with compared to 
individuals without MS (70). 
EFFECT OF DIETARY LIPIDS ON CIRCULATING 
ADIPONECTIN LEVELS
Intervention studies have shown that adiponectin levels 
can be partly determined by different types of diet. 
Given the important role of adiponectin in carbohydrate 
and lipid metabolism, including improving insulin 
sensitivity and increasing fatty acid oxidation, diets that 
modify the quantity and quality of lipids ingested can 
have an impact on the metabolism and plasma levels 
of adiponectin (71,72). Several studies conducted in 
humans aimed to show the effect of diets with high or 
low levels of total lipids in the regulation of adiponectin 
(73-75). In a randomized clinical trial comparing a fat-
restricted hypocaloric diet (27% fat, 52% carbohydrates, 
and 21% protein) vs. a high-fat diet (41% fat, 39% 
carbohydrates, and 20% protein), there were no 
changes in adiponectin levels observed at the end of 
10 weeks of intervention (73). However, another 
study that compared a normal-lipid hypocaloric diet 
(30% fat) vs. a high-lipid (61% fat) diet showed 30% 
and 18% increases in adiponectin levels after 52 weeks 
of intervention respectively (75). However, providing 
isocaloric diets for weight maintenance with high fat 
(55% fat, 27% carbohydrates, 18% protein) or low fat 
(20% fat, 62% carbohydrates, 18 % protein) was not 
associated with differences in adiponectin levels after 4 
weeks of intervention (74). These results suggest there 
is no consensus about the effect of total dietary lipid 
intake (low fat vs. high fat) on adiponectin levels in 
interventional studies conducted in humans. 
Greater adherence to the Mediterranean style diet, 
which is rich in unsaturated fats, has been associated 
with higher adiponectin levels (76). This relationship 
is possibly attributable not only to the low glycemic 
load and moderate alcohol consumption characteristic 
of this diet, but also to its high content of oilseeds 
and olive and fish oil, which are dietary sources of 
polyunsaturated fatty acids (71). The mechanisms 
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through which the Mediterranean diet has impacts on 
circulating levels of adiponectin is still unknown, but 
several hypotheses have been raised. The omega-3 
type polyunsaturated fatty acids (n-3 PUFA) found 
in this diet can modulate adiponectin levels by 
interacting with the peroxisome proliferator-activated 
receptors alpha (PPAR-α) and gamma (PPAR-g) (77). 
Activation of PPAR-α stimulated by consumption 
of n-3 PUFA increases expression of AdipoR1 and 
AdipoR2 in muscle and liver, improving sensitivity to 
this hormone in these tissues (78). Adiponectin then 
acts by reducing inflammation and oxidative stress, 
which ultimately leads to improved insulin sensitivity 
(79). Moreover, n-3 PUFAs activate PPAR-g, thus 
increasing adiponectin levels through a second route. 
In an experimental study, consumption of n-3 PUFAs 
was associated with a twofold increase in expression 
of the adiponectin gene, which occurred parallel to 
a twofold to threefold increase in expression of the 
gene which encodes PPAR-g (77). Thus, the activation 
of PPAR-α and PPAR-g promoted by n-3 PUFAs 
increases adiponectin levels and activity, which results 
in improvement in obesity-induced inflammation and 
insulin resistance (78).
In addition to the n-3 PUFAs, other types of 
lipids have shown effectiveness in the regulation of 
adiponectin, among which conjugated linoleic acid 
(CLA) stands out. CLA can cause resistance to insulin 
action by reducing plasma levels of adiponectin (80). 
The mRNA levels of adiponectin were reduced after 
CLA supplementation in rats (81) and in cultured 
human adipocyte cells (82). Since the adiponectin gene 
is modulated by activation of PPAR-g, suppression of 
the adiponectin gene can be partly attributed to the 
antagonistic effect of the trans-10, cis-12 CLA on 
PPAR-g (83).
Analysis of the results of clinical trials conducted 
across different ethnic groups, genders, metabolic 
profiles, and diseases provides an understanding of 
the effects of lipid intake on circulating levels of 
adiponectin. In this regard, a recent systematic review 
and meta-analysis performed by our group showed 
that, in intervention studies comparing low-fat vs. 
high-fat diets, there was no association of total amount 
of fat with circulating levels of adiponectin (72). 
Omega-3 PUFA supplementation modestly increased 
circulating concentrations of adiponectin; however, 
these findings should be interpreted with caution, since 
publication bias was identified in this meta-analysis (72). 
However, CLA supplementation reduced adiponectin 
concentrations as compared with unsaturated fatty acid 
supplementation as active placebo (72). 
CONCLUSIONS
Circulating levels of adiponectin are reduced in the 
presence of the MS, cardiovascular disease, and DM2, 
and also decrease as the number of MS components 
increases. The association of adiponectin with HDL 
cholesterol, triglycerides, and abdominal fat may 
partly explain the lower levels of adiponectin found in 
individuals with MS. Among dietary interventions, diets 
low in total lipids have shown no effect on circulating 
adiponectin. Supplementation with n-3 polyunsaturated 
fatty acids, however, was associated with a moderate 
increase in adiponectin. In contrast, conjugated 
linoleic acid appears to reduce adiponectin levels when 
compared to unsaturated fat supplementation.
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